

ACRUX RECEIVES SEVENTH US PATENT AND TERMINATES LICENCE TO NAPA BIOSCIENCES INC.

Acrux has been granted another patent in the USA (patent number 6,428,017), which provides additional protection for systemic delivery of anti-anxiety drugs. Acrux now has 7 granted US patents, which expire in February 2017. The new patent provides protection for transdermal drug delivery systems that consist of an effective amount of an anti-anxiety agent, a dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen, and a volatile liquid. This is a “continuation in part” patent, related to Acrux’s US patent number 6,818,226.

Acrux DDS Pty Ltd, a wholly owned subsidiary of Acrux Limited, has terminated the exclusive licence agreement signed in May 2005, under which Napa Biosciences Inc was to develop and commercialise certain prescription and over-the-counter dermatology products. As previously disclosed, it was a condition precedent for the licence grant to take effect that Napa Biosciences Inc raise US\$5 million in equity capital by 6 October 2005. Napa Biosciences Inc did not meet this condition. All intellectual property rights covered by the agreement remain with Acrux DDS Pty Ltd, which is now pursuing other options for realising value from its technology in this non-core area of dermatology.

Contact:

Igor Gonda, CEO & Managing Director

Tel: +61 3 8379 0100

About Acrux

www.acrux.com.au

- Acrux is a specialty pharmaceutical company, developing and commercialising a range of patented, patient-preferred healthcare products for global markets, using its innovative technology to administer drugs through the skin.
- Acrux’s product pipeline includes treatments of hormonal deficiencies, pain, central nervous system disorders and a contraceptive. 19 human clinical trials have been completed with 7 different drugs and the lead product, Evamist™, is currently in a phase 3 trial in the USA.
- Acrux has licensed USA rights for Evamist™ (Estradiol MDTS®) and Testosterone MDTS® to VIVUS and AUS/NZ distribution rights for Testosterone MDTS® and Fentanyl MDTS® to CSL Limited. Acrux has also licensed its technology to Eli Lilly for veterinary healthcare products.